Half The Experts Are Wrong (2.17.2023)

Save

Dr. Jack Cush reviews the news and tries to stump the expert panel this week on the podcast.

KNOW YOUR NUMBERS! (2.10.2023)

Save

Dr. Jack Cush reviews the news, journal articles and the numbers, from the past week on RheumNow.com

Burnout #10 (2.2.2023)

Save

Dr. Jack Cush reviews the past week of news on RheumNow.com

Simon Says “Don’t Do This” (1.27.2023)

Save

Dr. Jack Cush reviews this weeks journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything

The RheuNow Podcast Preview - Til Death Do Us Part (1.20.2023)

Save

Dr. Jack Cush reviews the highlights from the past week on RheumNow.com

Rheum Believe It Or Not (1.13.2023)

Save

Dr. Jack Cush reviews the notable standouts in the news since the 1st of January. Surprising reports on ferritin, alcohol benefits, cannabis for pain and a lower dementia risk with hydroxychloroquine.

RheumNow Podcast- 2022 Rheumatology Year in Review

Save

Dr. Jack Cush Reviews the highlight from 2022 in Rheumatology Check out the full podcast at RheumNow.com

Fever, FROST, & Pericarditis (12.16.2022)

Save

Dr. Jack Frost reviews the news and journal reports with a bonus audience question at the end.

Biosimilar Bonanza In 2023 (12.9.2022)

Save

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com

Rheum Manpower Needs - More Programs! (12.2.2022)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Biologics in Lupus – Why, Who, and When? Sponsored by GSK US Medical Affairs

Save

Leading experts from the SLE Educators’ Network discuss how biologic therapies may help address key unmet needs in lupus, while highlighting how clinicians can identify the most appropriate patients for biologic treatment.

Topic Podcasts - JAK TYK2

Save

ACR22 Year in Review Report Deucravacitinib in PsA JAK inhibitors in rheumatic diseases JAK vs TNF inhibitor Infections in RA New Treatments for SLE? Prelude to a Meeting (ACR22) (11.11.2022) Switching Between JAK Inhibiters in RA Tapering Methotrexate with Biologics or JAK Inhibitors in RA Tofacitinib and RA-ILD Upadacitinib vs Adalimumab in PsA u